1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDosemyc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.
Brennan J, O'Connor T, Makuch R, Simmons A, Russell E, Linnoila R, Phelps R, Gazdar A, Ihde D, Johnson B. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Research 1991, 51: 1708-12. PMID: 1847842.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationSmall cell lung cancerCell lung cancerLung cancerTumor cell linesExtensive-stage small-cell lung cancer patientsSmall cell lung cancer patientsCell linesPatient specimensCell lung cancer patientsDNA copy numberDifferent combination chemotherapyEtoposide/cisplatinDifferent chemotherapy regimensInitiation of therapyLung cancer patientsFrequency of amplificationChemotherapy regimensUntreated patientsCombination chemotherapyCancer patientsSame patientPatientsClinical situationsDNA amplification
1990
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrials
1988
Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases
Makuch R, Rosenberg P, Mulshine J. Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases. Statistics In Medicine 1988, 7: 843-856. PMID: 2842852, DOI: 10.1002/sim.4780070803.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesFunction testsOutcome dataSmall cell lung cancerImportant prognostic variablesCell lung cancerLogistic regression modelsPrognostic factorsLung cancerPrognostic variablesMetastasisBinary outcome dataSpecific guidelinesRegression modelsAgeStandard logistic regression model
1987
myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.
Johnson B, Ihde D, Makuch R, Gazdar A, Carney D, Oie H, Russell E, Nau M, Minna J. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. Journal Of Clinical Investigation 1987, 79: 1629-1634. PMID: 3034978, PMCID: PMC424486, DOI: 10.1172/jci112999.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationPatient tumorsTumor cell linesC-myc amplificationCell linesSmall cell lung cancer patientsCell lung cancer patientsSmall cell lung cancer cell linesCell lung cancer cell linesExtensive-stage patientsLung cancer patientsLung cancer cell linesCancer cell linesRelapsed patientsStage patientsClinical statusCancer patientsChemotherapy treatmentPatientsTumorsDNA amplificationOncogene amplification
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationChanges in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene.
Johnson B, Battey J, Linnoila I, Becker K, Makuch R, Snider R, Carney D, Minna J. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. Journal Of Clinical Investigation 1986, 78: 525-532. PMID: 3016030, PMCID: PMC423589, DOI: 10.1172/jci112604.Peer-Reviewed Original ResearchConceptsSmall cell lung cancer cell linesCell lung cancer cell linesLung cancer cell linesCancer cell linesBombesin-like immunoreactivityLarge cell morphologyC-myc messenger RNAC-myc expressionC-MycCell linesSmall cell lung cancerHuman small cell lung cancer cell linesCell lung cancerSmall cell lung cancer linesCell lung cancer linesMessenger RNALung cancer linesC-myc amplificationC-myc geneLung cancerVariant phenotypesCloning efficiencyDecarboxylase levelsCancer linesBiologic propertiesNon-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer
Johnson B, Ihde D, Matthews M, Bunn P, Zabell A, Makuch R, Johnston-early A, Cohen M, Glatstein E, Minna J. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. The American Journal Of Medicine 1986, 80: 1103-1110. PMID: 3014875, DOI: 10.1016/0002-9343(86)90672-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinomaCarcinoma, Small CellFemaleHumansLung NeoplasmsMaleMiddle AgedRadiographyTime FactorsConceptsSmall cell lung cancerCell lung cancerLung cancer deathsLung cancerCancer deathSame lobeSecond primary lung tumorsCancer-free survivorsDisease-free survivalPrimary lung tumorsSecond malignant tumorsRisk of developmentLate mortalityContralateral lungTherapeutic trialsInitial lesionLung tumorsMalignant tumorsHigh riskPatientsCancerDifferent lobesMajor causeDiagnosisStudy of menPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.
Johnson B, Becker B, Goff W, Petronas N, Krehbiel M, Makuch R, McKenna G, Glatstein E, Ihde D. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. Journal Of Clinical Oncology 1985, 3: 1659-67. PMID: 2999346, DOI: 10.1200/jco.1985.3.12.1659.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationMental status examinationLarge radiotherapy fractionsCranial irradiationStatus ExaminationScan abnormalitiesNeuropsychologic testingSmall-cell lung cancer trialHigh-dose induction chemotherapyLow-dose maintenance chemotherapySmall cell lung cancerRadiotherapy fractionsAbnormal neurologic examinationCranial tomography scanProgressive ventricular dilatationTherapeutic cranial irradiationTomography scan abnormalitiesHigh-dose chemotherapyStart of therapyLong-term survivorsLung cancer trialsMajority of casesCCT findingsInduction chemotherapyMaintenance chemotherapyPatients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
Johnson B, Ihde D, Bunn P, Becker B, Walsh T, Weinstein Z, Matthews M, Whang-Peng J, Makuch R, Johnston-Early A. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Annals Of Internal Medicine 1985, 103: 430-8. PMID: 2992337, DOI: 10.7326/0003-4819-103-3-430.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainCarcinoma, Small CellCombined Modality TherapyFemaleFollow-Up StudiesHematologic DiseasesHumansLung NeoplasmsMaleMemory DisordersMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRadiotherapyRespiratory Function TestsConceptsSmall cell lung cancerLung cancerCombination chemotherapyEvidence of cancerCancer-free survivalCell lung cancerCranial irradiationAggressive therapyLate toxicityUnrelated causesLate relapseTherapeutic trialsCancer 5PatientsPotential cureThirty-monthCancerChemotherapyRelapseCureChronic toxicityMonthsSurvivalEleven yearsToxicityThe role of radiation therapy in the treatment of small cell lung cancer
Lichter A, Bunn P, Ihde D, Cohen M, Makuch R, Carney D, Johnston‐Early A, Minna J, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985, 55: 2163-2175. PMID: 2983875, DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyCyclophosphamideDoxorubicinFollow-Up StudiesHumansLomustineLung NeoplasmsMethotrexateProcarbazineProspective StudiesRadiotherapyRadiotherapy DosageRandom AllocationTime FactorsVincristineWhole-Body IrradiationConceptsSmall cell lung cancerLimited-stage small cell lung cancerProphylactic cranial irradiationCell lung cancerCranial irradiationThoracic irradiationLung cancerExtensive-stage small-cell lung cancerComplete response statusLimited-stage diseaseOptimal treatment approachCombination of chemotherapyMinimum of toxicityLong-term survivalSystemic irradiationSystemic chemotherapyAggressive therapyPartial responseCNS failureResponse statusTreatment protocolOngoing protocolRadiation therapyTreatment approachesPatients
1984
Elevated serum creatine kinase BB levels in patients with small cell lung cancer.
Carney D, Zweig M, Ihde D, Cohen M, Makuch R, Gazdar A. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Research 1984, 44: 5399-403. PMID: 6091876.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerSerum CK-BBSerum CK-BB levelsCK-BB levelsCell lung cancerMetastatic sitesLung cancerCK-BBCreatine kinase BB levelsExtensive-stage diseaseSCLC cell linesClinical tumor specimensLimited diseaseClinical responseExtensive diseaseMetastatic diseaseUntreated patientsPretreatment stagingTumor disseminationTumor specimensPatientsBB isoenzymeBb levelsSignificant associationCreatine kinaseA comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer.
Crane J, Nelson M, Ihde D, Makuch R, Glatstein E, Zabell A, Johnston-Early A, Bates H, Saini N, Cohen M. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. Journal Of Clinical Oncology 1984, 2: 1017-24. PMID: 6088707, DOI: 10.1200/jco.1984.2.9.1017.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRadionuclide brain scanCell lung cancerBrain metastasesCT scanBrain scansAsymptomatic patientsNeurologic signsLung cancerExtensive-stage diseaseTherapeutic cranial irradiationTomographic brain scansCT brain scanSix-month intervalsCranial irradiationRN scansSCLC patientsAsymptomatic lesionsSymptomatic patientsSystemic therapyConsecutive patientsNeurologic historyComputed tomographyPatientsMetastasisDiagnosis and significance of liver metastases in small cell carcinoma of the lung.
Mulshine J, Makuch R, Johnston-Early A, Matthews M, Carney D, Ihde D, Cohen M, Bates H, Dunnick N, Minna J. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. Journal Of Clinical Oncology 1984, 2: 733-41. PMID: 6330314, DOI: 10.1200/jco.1984.2.7.733.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesLiver biopsyLiver scanFunction testsLiver evaluationSmall cell lung cancerNoninvasive procedureDisease-free survivorsPercutaneous liver biopsySmall cell carcinomaCell lung cancerRadionuclide liver scanResponse of patientsNational Cancer InstituteSuch metastasesLiver involvementConsecutive patientsStaging procedureHepatic metastasesPrognostic implicationsCell carcinomaPhysical examinationLung cancerCancer Institute
1983
Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy
Brower M, Ihde D, Johnston-Early A, Bunn P, Cohen M, Carney D, Makuch R, Matthews M, Radice P, Minna J. Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy. The American Journal Of Medicine 1983, 75: 993-1000. PMID: 6316784, DOI: 10.1016/0002-9343(83)90880-x.Peer-Reviewed Original ResearchConceptsHigh-intensity groupSmall cell bronchogenic carcinomaHigh-intensity therapyCell bronchogenic carcinomaInduction chemotherapyInduction courseInduction deathBronchogenic carcinomaDay 1Reversible congestive heart failureModerate-intensity therapyOverall median survivalCongestive heart failureSevere peripheral neuropathyModerate-intensity groupEvaluable patientsComplete remissionInduction therapyInfectious complicationsPartial remissionMedian survivalUntreated patientsComplete responseHeart failurePeripheral neuropathyIntensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapseDelayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer
Johnston‐Early A, Cohen M, Fossieck B, Harwood S, Ihde D, Bunn P, Matthews M, Minna J, Makuch R. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983, 52: 1395-1400. PMID: 6311393, DOI: 10.1002/1097-0142(19831015)52:8<1395::aid-cncr2820520810>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsSkin test reactivityGood performance statusLow tumor burdenTest reactivityAnergic patientsPerformance statusTumor burdenReactive patientsSmall cell lung cancer patientsHypersensitivity skin test reactivityCell lung cancer patientsSmall cell lung cancerGood prognosis patientsHypersensitivity skin testingCell lung cancerLung cancer patientsSkin test antigensPrognosis patientsSkin testingPoor prognosisPrognostic importancePrognostic utilityPrognostic indicatorCancer patientsLung cancerRole of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response
Rosen S, Makuch R, Lichter A, Ihde D, Matthews M, Minna J, Glatstein E, Bunn P. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response. The American Journal Of Medicine 1983, 74: 615-624. PMID: 6301274, DOI: 10.1016/0002-9343(83)91019-7.Peer-Reviewed Original ResearchConceptsCentral nervous system metastasesProphylactic cranial irradiationNervous system metastasesCranial irradiationComplete responsePrognostic featuresSystemic therapyCentral nervous system relapseSmall cell lung cancerInvolvement of liverPercent of patientsNervous system relapseSystemic combination chemotherapySubset of patientsTwo-year survivalCell lung cancerStage of diseaseCentral nervous systemNational Cancer InstituteChest irradiationComplete remissionEpidural metastasesOverall survivalCombination chemotherapyIntracerebral metastases